Abstract • 40

Ribomunyl comprises ribosomes of Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae, Klebsiella pneumoniae and membranous propteoglycans of K. pneumoniae. A meta-analysis has been conducted, using a statistical methodology previously employed and published, of all trials of Ribomunyl conducted according to Good Clinical Practice guidelines. Included in this meta-analysis have been 9 placebo-controlled, double-blind randomised trials; 4 comparative trials; and 17 open studies with historical comparison. No studies have been excluded thereby avoiding any possibility of publication bias. Principal outcomes include numbers of infections, numbers of prescriptions of antibiotics and days lost from school (or work). The purpose of the meta-analysis is to test for the homogeneity of the effect of Ribomunyl across studies and to quantify with precision the estimate of the effect